CLAIMS:

1. A compound of Formula III,



III

wherein

X and X' are each independently CR^8 or N; Y is independently N or $CR^{8'}$; provided that at least one of X, X' or Y is not N;

R^1 is C_1-C_6alkyl or C_1-C_6cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with deuterium, halogen, OH, cyano, C_1-C_3alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy or C_1-C_6alkylthiolyl;

R^{3a} and R^{3b} are each independently hydrogen or C_1-C_3alkyl;

R^4 for each occurrence (one, two, three, four or five) is independently and optionally halogen, C_1-C_6alkyl, C_2-C_6alkenyl -OR^5, $-(CR^{3a}R^{3b})_n$-(3- to 6- membered cycloalkyl), $-(CR^{3a}R^{3b})_n$-(4- to 6- membered heterocycloalkyl) wherein said alkyl, cycloalkyl or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, CN, -C(O)$(CH_2)_t$CN or -C_1-C_6alkoxy; -$NR^{11a}R^{11b}$; two R^4 taken together with the respective carbons to which each are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted with one to three F, Cl, OH, methyl, ethyl, propyl,

C_1-C_3fluoroalkyl, C_1-C_3difluoroalkyl, C_1-C_3trifluoroalkyl, C_1-C_3hydroxyalkyl, methoxy or ethoxy;

R^5 is hydrogen or C_1-C_6alkyl, wherein said alkyl is optionally substituted with fluoro;

R^8 is independently hydrogen, halogen, cyano, -$NR^{11a}R^{11b}$, C_1-C_6alkyl, 5- to 6-membered heteroaryl or aryl, wherein said alkyl or heteroaryl or aryl is optionally substituted with one, two or three halogen, -$NR^{11a}R^{11b}$, C_1-C_3 alkyl or oxo;

$R^{8'}$ is hydrogen, deuterium, halogen or cyano;

R^{10} is C_1-C_6alkyl, wherein said alkyl is optionally substituted with fluoro or cyano;

R^{11a} and R^{11b} are each independently hydrogen or C_1-C_6alkyl, wherein said alkyl is optionally substituted with OH;

n is independently 0 or 1; and

t is 1, 2 or 3;

or a pharmaceutically acceptable salt of said compound.

2. The compound of Claim 1 wherein Y is N; X and X' are CR^8; or a pharmaceutically acceptable salt of said compound.

3. The compound of Claim 1 wherein X and X' are each CR^8 and Y is $CR^{8'}$; or a pharmaceutically acceptable salt of said compound.

4. The compound of Claim 1 wherein X and Y are N and X' is CR^8; or a pharmaceutically acceptable salt thereof.

5. The compound of Claim 1 wherein X is N, X' is CR^8 and Y is $CR^{8'}$; or a pharmaceutically acceptable salt thereof.

6. The compound of Claim 2 wherein R^1 is C_1-C_3alkyl, wherein said alkyl is optionally substituted with one to three deuterium, F, Cl or C_1-C_3alkoxy; and R^{3a} and R^{3b} are each independently hydrogen or methyl; or a pharmaceutically acceptable salt of said compound.

7. The compound of Claim 6 wherein R^4 for each occurrence is independently and optionally F; Cl; OH; or C_1-C_3alkyl, optionally substituted with one to five deuterium, Cl, F, OH, C_1-C_3alkyl, or C_1-C_3alkoxy; or two R^4 taken together with the carbons to which they are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted with one to three Cl, F, OH, methyl, ethyl, propyl, C_1-C_3hydroxyalkyl, methoxy or ethoxy; or a pharmaceutically acceptable salt of said compound.

8. The compound of claim 7 wherein R^1 is methyl, ethyl, propyl or isopropyl wherein each of said R^1 moieties are optionally substituted with deuterium, fluoro or methoxy; or a pharmaceutically acceptable salt of said compound.

9. The compound of claim 8 wherein each R^4 is independently and optionally selected from fluoro, OH, methyl, ethyl, vinyl, propyl, wherein said methyl, ethyl, or propyl are optionally substituted with one, two or three fluoro, OH or methoxy; or two R^4 taken together with the carbons to which they are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl are optionally substituted with one to three Cl, F, OH, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethyl, propyl, C_1-C_3hydroxyalkyl, methoxy, or ethoxy; and

R^8 is independently hydrogen, halogen or C_1-C_6alkyl, wherein said alkyl is optionally substituted with fluoro;

or a pharmaceutically acceptable salt of said compound.

10. A compound of Formula IIIa,



IIIa

wherein

X and X' are each independently CR^8 or N; Y is independently N or $CR^{8'}$; provided that at least one of X, X' or Y is not N;

R^1 is C_1-C_6alkyl, wherein said alkyl is optionally substituted with deuterium, halogen, OH, C_1-C_3alkyl, C_3-C_6cycloalkyl or C_1-C_6alkoxy;

R^{3a} and R^{3b} are each independently hydrogen or C_1-C_3alkyl;

R^{4a} and R^{4b} are each independently hydrogen, deuterium, fluoro, OH, -OR^5, methyl, ethyl, vinyl, cyclopropyl or propyl, optionally substituted with one to five deuterium, fluoro, methoxy or OH;

R^{4c} and R^{4d} for each occurrence are independently and optionally halogen, OH, deuterium, C_1-C_6alkyl, C_2-C_6alkenyl, -OR^5, –$(CR^{3a}R^{3b})_n$-(3- to 6- membered cycloalkyl), or -$(CR^{3a}R^{3b})_n$-(4- to 6- membered heterocycloalkyl) wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally and independently substituted with one to five deuterium, halogen, OH, cyano, or C_1-C_6alkoxy; NH_2; or R^{4c} and R^{4d} taken together with the carbons to which they are bonded form a 4- to 7-membered heterocycloalkyl or a 3- to 7-membered cycloalkyl, wherein said heterocycloalkyl or cycloalkyl is optionally substituted with one to three fluoro, C_1-C_3alkyl or C_1-C_3fluoroalkyl; or

R^{4a} and R^{4c} taken together with the carbon to which they are bonded form a 4- to 7-membered heterocycloalkyl or a 3- to 7-membered cycloalkyl, wherein said

heterocycloalkyl or cycloalkyl is optionally substituted with one to three fluoro, C_1-C_3alkyl or C_1-C_3fluoroalkyl;

R^5 is hydrogen or C_1-C_6alkyl, wherein said alkyl is optionally substituted with fluoro;

R^8 is hydrogen, halogen or C_1-C_6alkyl, wherein said alkyl is optionally substituted with halogen;

$R^{8'}$ is hydrogen, deuterium, halogen or cyano; and

n is independently 0 or 1;

or a pharmaceutically acceptable salt of said compound or a tautomer of said compound or said salt.

11. The compound of Claim 10 wherein R^8 is hydrogen, methyl or fluoro; or a pharmaceutically acceptable salt of said compound or a tautomer of said compound or said salt.

12. The compound of Claim 11 wherein R^1 is methyl, ethyl, isopropyl or propyl, optionally substituted with deuterium; or a pharmaceutically acceptable salt of said compound or a tautomer of said compound or said salt.

13. The compound of Claim 12 wherein

R^{4a} is hydrogen; methyl, ethyl or propyl, optionally substituted with deuterium, fluoro, methoxy;

R^{4b} is hydrogen or fluoro;

R^{4c} is OH;

R^{4d} is fluoro, methoxy or OH; or methyl, optionally substituted with 1, 2 or 3 fluoro; or ethyl, optionally substituted with 1, 2, or 3 fluoro; or

R^{4c} and R^{4d} or alternatively R^{4a} and R^{4c} taken together with the carbons to which they are bonded form a cyclopropyl, optionally substituted with one to three fluoro, C_1-C_3alkyl or C_1-C_3fluoroalkyl;

or a pharmaceutically acceptable salt of said compound or a tautomer of said compound or said salt.

14. The compound:

5-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-3-(propan-2-yloxy)naphthalene-2-carboxamide;

1-{[(2S)-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

1-{[(2S,4S)-4-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

1-{[(2S,4S)-4-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

1-{[(2S,4S)-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

1-{[(2S)-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,4S)-5-oxo-4-(2,2,2-trifluoroethyl)pyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

1-{[(2S,3S,4R)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

3-methoxy-5-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}naphthalene-2-carboxamide;

1-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S)-4,4-difluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

1-{[(2S,3S,4R)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

5-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2-yl]methoxy}-3-methoxynaphthalene-2-carboxamide;

1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S)-3-ethyl-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

5-{[(2S,4R)-4-fluoro-4-(hydroxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-3-methoxynaphthalene-2-carboxamide;

7-methoxy-1-{[(2S,3R)-3-methyl-5-oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide;

1-{[(2S,4S)-4-fluoro-4-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

3-methoxy-5-{[(2S,3R)-3-methyl-5-oxopyrrolidin-2-yl]methoxy}naphthalene-2-carboxamide;

5-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-3-methoxynaphthalene-2-carboxamide;

8-fluoro-5-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-3-methoxynaphthalene-2-carboxamide;

5-{[(2S,4R)-4-fluoro-5-oxo-4-(2,2,2-trifluoroethyl)pyrrolidin-2-yl]methoxy}-3-methoxynaphthalene-2-carboxamide;

1-{[(2S,3S)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

4-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinoline-7-carboxamide;

1-{[(2S,3S)-3-ethenyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,4S)-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,4S)-4-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

4-{[(2S,4S)-4-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinoline-7-carboxamide;

4-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2-yl]methoxy}-6-(propan-2-yloxy)quinoline-7-carboxamide;

7-ethoxy-1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide;

7-ethoxy-1-{[(2S,4S)-4-fluoro-4-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S)-3-cyclopropyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

7-methoxy-1-{[(2S,3R)-5-oxo-3-propylpyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide;

4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinoline-7-carboxamide;

1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-[(trideuterium)methyloxy]isoquinoline-6-carboxamide;

4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinazoline-7-carboxamide;

1-{[(2S,3S,4R)-3-ethyl-4-methoxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-(pentadeuterium)ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S)-3-ethyl-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R)-4,4-difluoro-3-(methoxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R,4S)-4-fluoro-3-(methoxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

7-methoxy-1-{[(2S,3S,4R)-4-methoxy-3-methyl-5-oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide;

1-{[(2S,3R,4R)-4-fluoro-3-(methoxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4R)-3-ethyl-4-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S)-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

7-ethoxy-1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-4-fluoro-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-8-fluoro-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-4-fluoro-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-8-fluoro-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R)-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-cyclopropyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4R)-3-cyclopropyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

4-(1-methyl-1H-imidazol-4-yl)-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

4-(1,2-dimethyl-1H-imidazol-4-yl)-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

4-(2-methyl-1H-imidazol-4-yl)-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

4-(2-methyl-1H-imidazol-4-yl)-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo(3,4-bisdeuterium)pyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinoline-7-carboxamide; or

1-{[(2S,3R,4R)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

or a pharmaceutically acceptable salt of said compound.

15. The compound:

1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinazoline-7-carboxamide;

1-{[(2S,3R,4S)-4-fluoro-3-(methoxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4R)-3-ethyl-4-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S)-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinoline-7-carboxamide; or

1-{[(2S,3R,4R)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

or a pharmaceutically acceptable salt thereof.

16. 1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

17. 1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

18. 1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

19. 1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

20. 4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinazoline-7-carboxamide, or a pharmaceutically acceptable salt thereof.

21. 7-methoxy-1-{[(1S,2S,5R)-6-methyl-4-oxo-3-azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

22. 1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

23. 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

24. 1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

25. Use of a compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, for treating an autoimmune disease; inflammatory disease; autoinflammatory condition; pain condition; respiratory; airway or pulmonary condition; gastrointestinal (GI) disorder; allergic disease; infection-based disease; trauma or tissue injury-based condition; fibrotic disease; disease driven by over-activity of IL1 pathways; ophthalmic/ocular disease; joint, muscle or bone disorder; skin/dermatological disease; renal disease; genetic disease; hematopoietic disease; liver disease; oral disease; metabolic disease, diabete or complication thereof; proliferative disease; cardiovascular condition; vascular condition; neuroinflammatory condition; neurodegenerative condition; cancer; sepsis; pulmonary inflammation or injury; or pulmonary hypertension.

26. The use according to Claim 25 wherein the disease or condition is systemic lupus erthematosus (SLE), lupus nephritis, rheumatoid arthritis, psoriasis, atopic dermatitis, gout, cryopyrin-associated periodic syndrome (CAPS), diffuse large B cell lymphoma (DLBCL), chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disorder (COPD), asthma or bronchospasm.

27. A pharmaceutical composition comprising a compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle, diluents or carrier.

28. A pharmaceutical combination comprising:

a first compound, the first compound being a compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof;

a second compound, the second compound being a compound useful for the treatment of systemic lupus erthematosus (SLE), lupus nephritis, rheumatoid arthritis, psoriasis, atopic dermatitis, gout, cryopyrin-associated periodic syndrome (CAPS), diffuse large B cell lymphoma (DLBCL), chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disorder (COPD), asthma or bronchospasm; and

an optional pharmaceutically acceptable carrier, vehicle or diluent.

29. A pharmaceutical combination comprising:

a first compound, the first compound being a compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof;

a second compound, the second compound being a non-steroidal anti-inflammatory drug, immunomodulatory and/or anti-inflammatory agent, antimalarial, antibiotic, anti-TNFα agent, anti-CD20 agent, antidiarrheal, bile acid binding agent, laxative; T lymphocyte activation inhibitor, anti-IL1 treatment, glucocorticoid receptor modulator, aminosalicyic acid derivative, sulfasalazine, mesalazine, anti-α4 integrin agent, α1- or α2-adrenergic agonist agent, β-adrenergic agonist, anticholinergic agent, inhaled long acting beta-agonist, long acting muscarinic antagonist, long acting corticosteroid, leukotriene pathway modulator, H1 receptor antagonist, PDE4 inhibitor, Vitamin D receptor modulator, Nrf2 pathway activator, modulator of the RAR-related orphan receptor (ROR) family, modulator and/ or antagonist of the

chemokine receptor, a prostaglandin, PDE5 inhibitor, endothelin receptor antagonist, soluble guanylate cyclase activator, an interferon, sphingosine 1-phosphate receptor modulator, inhibitor of the complement pathway, inhibitor of a Janus kinase, inhibitor of more of JAK1, JAK2, JAK3, or TYK2; inhibitor of an anti-inflammatory or immunomodulatory kinase, antioxidant, inhibitor of IL5, inhibitor of IL4, inhibitor of IL13, anti-IL6 agent, inhibitor/antagonist of IL17/IL17R, antagonist of IL12 and/or IL23, inhibitor of IL33, inhibitor of IL9, inhibitor of GM-CSF, anti CD4 agent, CRTH2 antagonist, inhibitor of B lymphocyte stimulator, CD22-specific monoclonal antibody, inhibitor of interferon-α, inhibitor of type I interferon receptor, FcγRIIB agonist, modified and/or recombinant version of Heat Shock Protein 10, inhibitor of the TNF superfamily receptor 12A, inhibitor of xanthine, inhibitor of URAT1, agent for the treatment of gout and/ or lowering of uric acid level, inhibitor of a toll-like receptor, agonist of TLR, Activator SIRT1, A3 receptor agonist, agent for the treatment of psoriasis, antifibrotic agent, prolyl hydroxylase inhibitor, inhibitor of granulocyte macrophage colony-stimulating factor, inhibitor of MAdCAM, inhibitor of connective tissue growth factor (CTGF), inhibitor of cathepsin C, inhibitor of soluble epoxide hydrolase, inhibitor of the TNFR1 associated death domain protein, anti-CD19 agent, anti-B7RP1 agent, inhibitor of ICOS ligand, inhibitor of thymic stromal lymphoprotein, inhibitor of IL2, inhibitor of leucine rich repeat neuronal protein 6A, inhibitor of an integrin, anti-CD40L agent, modulator of the dopamine D3 receptor, inhibitor/modulator of a galectin-3, agent for treating diabetic nephropathy, agent for treating acute kidney injury, modulator of an inflammasome, modulator of a bromodomain, modulator of a GPR43 or inhibitor of a TRP channel; and

an optional pharmaceutically acceptable carrier, vehicle or diluent.

30. The pharmaceutical combination of Claim 29 wherein the second compound is selected from the group consisting of a corticosteroid, hydroxychloroquine, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, janus kinase inhibitor, statin, calcipotriene, angiotensin-converting enzyme inhibitor and angiotensin receptor blocker; and

an optional pharmaceutically acceptable carrier, excipient or diluents.

31. The composition of Claim 30 wherein the second compound is a janus kinase inhibitor.

32. The composition of Claim 31 wherein the janus kinase inhibitor is ruxolitinib, baricitinib, tofacitinib, Decernotinib, Cerdulatinib, JTE-052, Peficitinib, GLPG-0634, INCB-47986, INCB-039110, PF-04965842, XL-019, ABT-494, R-348, GSK-2586184, AC-410, BMS-911543 or PF-06263276.

33. 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide.